A Phase I/II signal finding study of AEVI-002 in severe pediatric onset Crohn's disease.
Phase of Trial: Phase I/II
Latest Information Update: 09 Aug 2017
At a glance
- Drugs AEVI 002 (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; Therapeutic Use
- 09 Aug 2017 According to an Aevi Genomic Medicine media release, initial data is anticipated around year-end 2017.
- 15 Mar 2017 New trial record
- 09 Mar 2017 According to an Aevi Genomic Medicine media release, company anticipates announcing data from this study during second half of 2017.